Indications and uses
helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun
CLE DE PEAU BEAUTE SILKY FOUNDATION I
- Manufacturer
- SHISEIDO CO., LTD.
- Effective date
- 2012-04-12
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:47:41
Label at a glance#
ProductCLE DE PEAU BEAUTE SILKY FOUNDATION I BF20
Active ingredientOctinoxate, Titanium dioxide
Label structure17 sections
Dosage and administration
For sunscreen use: apply liberally 15 minutes before sun exposure use a water resistant sunscreen if swimming or sweating reapply at least every 2 hours Sun Protection Measures . Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the su...
Storage and handling
protect this product in this container from excessive heat and direct sun.
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
OTC - PURPOSE SECTION
| Active ingredients | Purpose | |
|---|---|---|
| OCTINOXATE | 1.9% | Sunscreen |
| TITANUIM DIOXIDE | 4.1% | Sunscreen |
Uses
- helps prevent sunburn
- if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun
Warnings
For external use only
OTC - DO NOT USE SECTION
Do not use on damaged or broken skin
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.
Directions
For sunscreen use:
- apply liberally 15 minutes before sun exposure
- use a water resistant sunscreen if swimming or sweating
- reapply at least every 2 hours
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:
- limit time in the sun, especially from 10 a.m. – 2 p.m.
- wear long-sleeve shirts, pants, hats, and sunglasses
- children under 6 months: Ask a doctor
Inactive Ingredients
WATER • DIMETHICONE • GLYCERIN • DIPHENYLSILOXY PHENYL TRIMETHICONE • BUTYLENE GLYCOL • DIETHYLHEXYL SUCCINATE • LAURYL PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE • PEG-10 DIMETHICONE • DIMETHICONE/PHENYL VINYL DIMETHICONE CROSSPOLYMER • DISTEARDIMONIUM HECTORITE • CYCLOMETHICONE • POLYGLYCERYL-2 DIISOSTEARATE • BARIUM SULFATE • NYLON-12 • DIPENTAERYTHRITYL HEXAHYDROXYSTEARATE • POLYMETHYL METHACRYLATE • SODIUM HYALURONATE • SODIUM ACETYLATED HYALURONATE • ROSA ROXBURGHII FRUIT EXTRACT • ORIGANUM MAJORANA LEAF EXTRACT • LILIUM CANDIDUM BULB EXTRACT • ALUMINUM HYDROXIDE • ALUMINUM DISTEARATE • ALUMINA • TRISODIUM EDTA • TRIETHOXYCAPRYLYLSILANE • VINYL DIMETHICONE/METHICONE SILSESQUIOXANE CROSSPOLYMER • POLYSILICONE-2 • BHT • SYNTHETIC FLUORPHLOGOPITE • TOCOPHEROL • TRIETHOXYSILYLETHYL POLYDIMETHYLSILOXYETHYL DIMETHICONE • PHENOXYETHANOL • SODIUM DEHYDROACETATE • FRAGRANCE • TITANIUM DIOXIDE • IRON OXIDES • MICA
Other information
- protect this product in this container from excessive heat and direct sun.
Questions or comments?
Call toll free 1-800-906-7503
SPL UNCLASSIFIED SECTION
Manufactured by
SHISEIDO CO., LTD.
7-5-5 GINZA TOKYO
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - BF20
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - I10
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O10
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O20
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O30
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B10
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B20
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B30
clé de peau
BEAUTÉ
silky cream foundation
BROAD SPECTRUM SPF 23
SUNSCREEN
25mL NET WT. .91 OZ.
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 2 | |
| Titanium dioxide | ACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 2 | |
| Titanium dioxide | ACTIVE MOIETY | 15FIX9V2JP | 2 | |
| .ALPHA.-TOCOPHEROL | INACTIVE INGREDIENT | H4N855PNZ1 | 2 | |
| ALUMINUM DISTEARATE | INACTIVE INGREDIENT | 7P1HP1B9UI | 2 | |
| ALUMINUM HYDROXIDE | INACTIVE INGREDIENT | 5QB0T2IUN0 | 2 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 2 | |
| BARIUM SULFATE | INACTIVE INGREDIENT | 25BB7EKE2E | 2 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 2 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| CYCLOMETHICONE | INACTIVE INGREDIENT | NMQ347994Z | 2 | |
| DIETHYLHEXYL SUCCINATE | INACTIVE INGREDIENT | 69W9UMG3P8 | 2 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 2 | |
| EDETATE TRISODIUM | INACTIVE INGREDIENT | 420IP921MB | 2 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 2 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 2 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 2 | |
| LILIUM CANDIDUM BULB | INACTIVE INGREDIENT | AHG15J8AM0 | 2 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 2 | |
| NYLON-12 | INACTIVE INGREDIENT | 446U8J075B | 2 | |
| ORIGANUM MAJORANA WHOLE | INACTIVE INGREDIENT | R40XM3HU5X | 2 | |
| PEG-10 DIMETHICONE (600 CST) | INACTIVE INGREDIENT | 8PR7V1SVM0 | 2 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| ROSA ROXBURGHII FRUIT | INACTIVE INGREDIENT | CVT1AA87FF | 2 | |
| SODIUM DEHYDROACETATE | INACTIVE INGREDIENT | 8W46YN971G | 2 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| TRIETHOXYCAPRYLYLSILANE | INACTIVE INGREDIENT | LDC331P08E | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- CLE DE PEAU BEAUTE SILKY FOUNDATION I BF20
- Octinoxate and Titanium dioxide
- Octinoxate
- Titanium dioxide
- WATER
- DIMETHICONE
- GLYCERIN
- BUTYLENE GLYCOL
- FERRIC OXIDE RED
- FERROSOFERRIC OXIDE
- FERRIC OXIDE YELLOW
- DIETHYLHEXYL SUCCINATE
- PEG-10 DIMETHICONE (600 CST)
- BARIUM SULFATE
- NYLON-12
- CYCLOMETHICONE
- PHENOXYETHANOL
- ALUMINUM HYDROXIDE
- ALUMINUM DISTEARATE
- ALUMINUM OXIDE
- EDETATE TRISODIUM
- SODIUM DEHYDROACETATE
- TRIETHOXYCAPRYLYLSILANE
- MICA
- HYALURONATE SODIUM
- BUTYLATED HYDROXYTOLUENE
- ORIGANUM MAJORANA WHOLE
- ROSA ROXBURGHII FRUIT
- .ALPHA.-TOCOPHEROL
- LILIUM CANDIDUM BULB
- CLE DE PEAU BEAUTE SILKY FOUNDATION I I10
- CLE DE PEAU BEAUTE SILKY FOUNDATION I O10
- CLE DE PEAU BEAUTE SILKY FOUNDATION I O20
- CLE DE PEAU BEAUTE SILKY FOUNDATION I O30
- CLE DE PEAU BEAUTE SILKY FOUNDATION I B10
- CLE DE PEAU BEAUTE SILKY FOUNDATION I B20
- CLE DE PEAU BEAUTE SILKY FOUNDATION I B30
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 52685-356 | 52685-356-60 |
| 52685-357 | 52685-357-60 |
| 52685-358 | 52685-358-60 |
| 52685-359 | 52685-359-60 |
| 52685-360 | 52685-360-60 |
| 52685-361 | 52685-361-60 |
| 52685-362 | 52685-362-60 |
| 52685-363 | 52685-363-60 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CYCLOMETHICONE | CYCLOMETHICONE | NMQ347994Z | LOTION / TOPICAL | 3510 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| EDETATE TRISODIUM | EDETATE TRISODIUM | 420IP921MB | CREAM / TOPICAL | NA | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | CAPSULE / ORAL | 14 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| CYCLOMETHICONE | CYCLOMETHICONE | NMQ347994Z | CREAM / TOPICAL | 13 %w/w | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, CHEWABLE / ORAL | 14 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET, EXTENDED RELEASE / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SWAB / TOPICAL | 0.5 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | OINTMENT / TOPICAL | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, LIQUID FILLED / ORAL | 0.1 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.64 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY, METERED / NASAL | 0.1 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | DROPS / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | TABLET / ORAL | 3 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GUM, CHEWING / BUCCAL | 5 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE, COATED / ORAL | 17 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 0.15 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | PASTE / DENTAL | 0.5 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET / ORAL | 232 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GEL / TOPICAL | 0.06 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | POWDER, FOR SUSPENSION / ORAL | 1 mg | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / OPHTHALMIC | 3 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | TABLET, FILM COATED / ORAL | 246 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM, SOLUBLE / BUCCAL | 11 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TOPICAL | 1400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, COATED / ORAL | 49 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION / INTRAVENOUS | NA | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET / ORAL | 2 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | GRANULE, FOR SUSPENSION / ORAL | 143 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOAP / TOPICAL | 0.02 %w/w | ||
| CYCLOMETHICONE | CYCLOMETHICONE | NMQ347994Z | AEROSOL, FOAM / TOPICAL | 5.26 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | LOTION / TOPICAL | 1 %w/w | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, COATED / ORAL | 1 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| BARIUM SULFATE | BARIUM SULFATE | 25BB7EKE2E | SUPPOSITORY, EXTENDED RELEASE / INTRAUTERINE | 10 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, EXTENDED RELEASE / ORAL | 90 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 28905d0a-07ee-4ffb-9e9f-a8f3a7b8deb7 | acde72ef-ee56-4951-a479-139f68b0c4ac | 2023-09-20 | Warnings | acde72ef-ee56-4951-a479-139f68b0c4ac |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.